Amedisys, Inc. (AMED)
$
100.99
+0.01 (0.01%)
Key metrics
Financial statements
Free cash flow per share
7.1544
Market cap
3.3 Billion
Price to sales ratio
1.3825
Debt to equity
0.3662
Current ratio
1.3560
Income quality
2.9080
Average inventory
0
ROE
0.1270
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Amedisys, Inc., along with its subsidiaries, is a prominent provider of healthcare services across the United States, operating through several segments including Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health division ensures patients recovering from surgery, chronic disabilities, or terminal illnesses receive comprehensive care at home, aiming to mitigate avoidable hospital readmissions through skilled nursing staff, specialized rehabilitation therapists in physical, speech, and occupational therapy, as well as supportive social workers and aides. The Hospice segment is dedicated to offering comfort and support to patients facing terminal illnesses such as cancer, heart disease, pulmonary disease, or Alzheimer's. Within the Personal Care segment, assistance is provided for daily living activities, ensuring patients maintain their quality of life. The High Acuity Care segment delivers key elements of inpatient hospital care, skilled nursing care, and palliative care within patients' homes. As of December 31, 2021, Amedisys, Inc. operated 331 home health care centers, 175 hospice care centers, and 14 personal-care centers, along with 8 high acuity care centers, spanning 38 states and the District of Columbia. The company was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana. The diluted EPS is $1.31 accounting for potential share dilution. The company incurred an income tax expense of $48,054,000.00 indicating its tax obligations. The financial data pertains to the fiscal year 2024. The operating income ratio is 0.04 indicating the company's operational profitability margin. The company reported an income before tax of $86,216,000.00 showcasing its pre-tax profitability. The stock is reasonably priced at $97.79 appealing to a broad range of investors. With an average trading volume of 517,900.00 the stock indicates moderate liquidity. Amedisys, Inc. has a mid-range market capitalization of $3,321,328,621.00 characterizing it as a steady performer in the market. It is a key player in the Medical - Care Facilities industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Analysts predict Amedisys, Inc. stock to fluctuate between $82.15 (low) and $101.02 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-08-14, Amedisys, Inc.'s market cap is $3,321,328,621, based on 32,887,698 outstanding shares.
Compared to Eli Lilly & Co., Amedisys, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Amedisys, Inc. (AMED) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AMED. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Amedisys, Inc.'s last stock split was 4:3 on 2006-12-05.
Revenue: $2,348,324,000 | EPS: $1.32 | Growth: -540%.
Visit https://www.amedisys.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $219.06 (2021-08-05) | All-time low: $69.37 (2023-03-23).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
AMED's planned merger with UnitedHealth remains on the rocks with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Amedisys (AMED) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.32 per share a year ago.
globenewswire.com
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.
zacks.com
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
zacks.com
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com
Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
zacks.com
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
See all news